Enveric Biosciences Future Growth

Future criteria checks 0/6

Enveric Biosciences is forecast to grow earnings and revenue by 15.3% and 52.5% per annum respectively while EPS is expected to grow by 70.5% per annum.

Key information

15.3%

Earnings growth rate

70.5%

EPS growth rate

Pharmaceuticals earnings growth	23.8%
Revenue growth rate	52.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:ENVB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	5	-17	-8	-8	2
12/31/2025	5	-14	-3	-3	2
12/31/2024	N/A	-18	-11	-11	2
12/31/2023	N/A	-17	-14	-14	N/A
9/30/2023	N/A	-23	-16	-16	N/A
6/30/2023	N/A	-23	-18	-18	N/A
3/31/2023	N/A	-19	-18	-18	N/A
12/31/2022	N/A	-19	-18	-17	N/A
9/30/2022	N/A	-52	-19	-18	N/A
6/30/2022	N/A	-52	-16	-15	N/A
3/31/2022	N/A	-50	-14	-13	N/A
12/31/2021	N/A	-49	-12	-11	N/A
9/30/2021	N/A	-11	-10	-10	N/A
6/30/2021	N/A	-9	-9	-8	N/A
3/31/2021	N/A	-9	-7	-6	N/A
12/31/2020	N/A	-7	-4	-4	N/A
9/30/2020	N/A	-3	-2	-2	N/A
6/30/2020	N/A	-3	-1	-1	N/A
3/31/2020	N/A	-3	-1	-1	N/A
12/31/2019	N/A	-2	-1	-1	N/A
9/30/2019	N/A	-3	-1	-1	N/A
12/31/2018	N/A	-2	-1	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENVB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ENVB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ENVB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ENVB is forecast to have no revenue next year.

High Growth Revenue: ENVB is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ENVB's Return on Equity is forecast to be high in 3 years time

Enveric Biosciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.

New major risk - Share price stability

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Enveric Biosciences Receives Notice from the Nasdaq Stock Market

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of Psilocin

High number of new and inexperienced directors

Enveric Biosciences, Inc. Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

Enveric Biosciences, Inc., Annual General Meeting, Oct 28, 2022

Enveric Biosciences, Inc. Appoints Robert Dickey IV as Chief Financial Officer

Enveric Biosciences, Inc. Regains Compliance with Listing Rule 5550(a)(2) Letter from the Listing Qualifications Department of Nasdaq

Enveric Biosciences, Inc. Appoints New Independent Directors

Enveric Biosciences, Inc. announced that it expects to receive $5 million in funding

Enveric Biosciences to raise $8M in stock offering for corporate use

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors

Enveric Biosciences Announces Management Appointments

High number of new and inexperienced directors

Enveric Biosciences, Inc. Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences, Inc. announces development of EV104a and EV104b

Enveric Biosciences Goes Psychedelic With MagicMed Acquisition

Enveric Biosciences, Inc. (NasdaqCM:ENVB) entered into a definitive agreement to acquire MagicMed Industries Inc.

Enveric Biosciences, Inc. announced delayed annual 10-K filing

Enveric Biosciences, Inc. Appoints Dr. Douglas D. Lind to Company's Board of Directors

Enveric Biosciences, Inc. (NasdaqCM:ENVB) completed the acquisition of Exclusive and perpetual license for Diverse Biotech novel molecules from Diverse Biotech, Inc.

Enveric Biosciences announces $10M registered direct offering

Enveric Biosciences Inc. Appoints Dr. Marcus Schabacker to Board of Directors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies